Entera Bio Stock Cash Flow From Operations

ENTX Stock

USD 1.59 0.03 1.85%

Entera Bio fundamentals help investors to digest information that contributes to Entera Bio's financial success or failures. It also enables traders to predict the movement of Entera Stock. The fundamental analysis module provides a way to measure Entera Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entera Bio stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Entera Bio Company Cash Flow From Operations Analysis

Entera Bio's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current Entera Bio Cash Flow From Operations

(7.31 M)

Most of Entera Bio's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entera Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Entera Cash Flow From Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for Entera Bio is extremely important. It helps to project a fair market value of Entera Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Entera Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entera Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entera Bio's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Net Invested Capital	Net Working Capital	Current Deferred Revenue	Net Receivables	Capital Surpluse	Long Term Debt Total	Common Stock
Total Assets		0.82	0.81	-0.96	-0.72	-0.25	-0.82	-0.64	0.72	1.0	-0.6	-0.52	0.61	0.85	0.65	-0.13	-0.67	0.65	-0.21	-0.59
Total Stockholder Equity	0.82		1.0	-0.88	-0.88	-0.51	-0.74	-0.96	0.72	0.82	-0.92	-0.72	0.69	1.0	0.4	0.02	-0.84	0.83	-0.36	-0.76
Net Tangible Assets	0.81	1.0		-0.88	-0.9	-0.53	-0.74	-0.97	0.72	0.82	-0.92	-0.75	0.67	0.99	0.4	0.0	-0.86	0.84	-0.41	-0.78
Net Debt	-0.96	-0.88	-0.88		0.83	0.26	0.78	0.74	-0.85	-0.96	0.64	0.63	-0.66	-0.91	-0.52	0.05	0.78	-0.77	0.28	0.7
Retained Earnings	-0.72	-0.88	-0.9	0.83		0.64	0.75	0.85	-0.71	-0.73	0.77	0.9	-0.55	-0.88	-0.29	0.06	0.96	-0.92	0.61	0.91
Accounts Payable	-0.25	-0.51	-0.53	0.26	0.64		0.4	0.58	-0.02	-0.26	0.69	0.63	-0.31	-0.47	-0.17	0.02	0.68	-0.65	0.43	0.74
Long Term Debt	-0.82	-0.74	-0.74	0.78	0.75	0.4		0.61	-0.66	-0.82	0.65	0.58	-0.56	-0.77	-0.2	-0.08	0.66	-0.65	0.32	0.59
Total Liab	-0.64	-0.96	-0.97	0.74	0.85	0.58	0.61		-0.63	-0.64	0.95	0.73	-0.64	-0.95	-0.24	-0.08	0.83	-0.81	0.41	0.75
Short Long Term Debt	0.72	0.72	0.72	-0.85	-0.71	-0.02	-0.66	-0.63		0.72	-0.46	-0.45	0.53	0.77	0.15	0.12	-0.61	0.7	-0.09	-0.55
Total Current Assets	1.0	0.82	0.82	-0.96	-0.73	-0.26	-0.82	-0.64	0.72		-0.6	-0.53	0.59	0.85	0.65	-0.14	-0.68	0.65	-0.21	-0.6
Short Term Debt	-0.6	-0.92	-0.92	0.64	0.77	0.69	0.65	0.95	-0.46	-0.6		0.67	-0.63	-0.89	-0.23	-0.09	0.76	-0.75	0.36	0.68
Intangible Assets	-0.52	-0.72	-0.75	0.63	0.9	0.63	0.58	0.73	-0.45	-0.53	0.67		-0.51	-0.69	-0.2	0.09	0.94	-0.84	0.86	0.81
Property Plant Equipment	0.61	0.69	0.67	-0.66	-0.55	-0.31	-0.56	-0.64	0.53	0.59	-0.63	-0.51		0.69	0.09	0.58	-0.66	0.66	-0.15	-0.55
Net Invested Capital	0.85	1.0	0.99	-0.91	-0.88	-0.47	-0.77	-0.95	0.77	0.85	-0.89	-0.69	0.69		0.39	0.03	-0.83	0.83	-0.33	-0.75
Net Working Capital	0.65	0.4	0.4	-0.52	-0.29	-0.17	-0.2	-0.24	0.15	0.65	-0.23	-0.2	0.09	0.39		-0.56	-0.29	0.21	-0.09	-0.29
Current Deferred Revenue	-0.13	0.02	0.0	0.05	0.06	0.02	-0.08	-0.08	0.12	-0.14	-0.09	0.09	0.58	0.03	-0.56		0.0	0.06	0.25	-0.12
Net Receivables	-0.67	-0.84	-0.86	0.78	0.96	0.68	0.66	0.83	-0.61	-0.68	0.76	0.94	-0.66	-0.83	-0.29	0.0		-0.96	0.64	0.89
Capital Surpluse	0.65	0.83	0.84	-0.77	-0.92	-0.65	-0.65	-0.81	0.7	0.65	-0.75	-0.84	0.66	0.83	0.21	0.06	-0.96		-0.47	-0.85
Long Term Debt Total	-0.21	-0.36	-0.41	0.28	0.61	0.43	0.32	0.41	-0.09	-0.21	0.36	0.86	-0.15	-0.33	-0.09	0.25	0.64	-0.47		0.52
Common Stock	-0.59	-0.76	-0.78	0.7	0.91	0.74	0.59	0.75	-0.55	-0.6	0.68	0.81	-0.55	-0.75	-0.29	-0.12	0.89	-0.85	0.52

Click cells to compare fundamentals

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Competition

Predict Entera Bio

Total Cash From Operating Activities Over Time

In accordance with the recently published financial statements, Entera Bio has (7.31 Million) in Cash Flow From Operations. This is 101.39% lower than that of the Biotechnology sector and 111.69% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.75% higher than that of the company.

Entera Cash Flow From Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entera Bio's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics of similar companies.

Entera Bio is currently under evaluation in cash flow from operations category among its peers.

Entera Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Entera Bio from analyzing Entera Bio's financial statements. These drivers represent accounts that assess Entera Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entera Bio's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	26.0M	19.9M	73.7M	21.0M	17.4M	16.5M
Enterprise Value	11.1M	11.7M	49.1M	8.8M	6.8M	6.4M

Entera Fundamentals

	Return On Equity	-1.45
	Return On Asset	-0.71
	Operating Margin	(71.93) %
	Current Valuation	51.96 M
	Shares Outstanding	36.83 M
	Shares Owned By Insiders	19.01 %
	Shares Owned By Institutions	18.93 %
	Number Of Shares Shorted	44.15 K
	Price To Earning	2.10 X
	Price To Book	9.08 X
	Price To Sales	591.55 X
	Revenue	14 K
	Gross Profit	33 K
	EBITDA	(8.8 M)
	Net Income	(8.89 M)
	Cash And Equivalents	17.28 M
	Cash Per Share	0.60 X
	Total Debt	390 K
	Debt To Equity	0.01 %
	Current Ratio	10.89 X
	Book Value Per Share	0.18 X
	Cash Flow From Operations	(7.31 M)
	Short Ratio	1.98 X
	Earnings Per Share	(0.26) X
	Target Price	10.0
	Number Of Employees	17
	Beta	1.59
	Market Capitalization	58.56 M
	Total Asset	11.77 M
	Retained Earnings	(104.39 M)
	Working Capital	10.17 M
	Current Asset	8.46 M
	Current Liabilities	7.64 M
	Net Asset	11.77 M

About Entera Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Entera Stock Analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC